The effect of antidiabetic drugs on genes regulating lipid metabolism

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Opinion in Lipidology

• Publication date

  2009-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/MOL.0b013e32831ac56cPMID 19106706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption.

  2008cited by this paper
• Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP

  2008cited by this paper
• The intestine as a regulator of cholesterol homeostasis in diabetes.

  2008cited by this paper
• Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

  2008cited by this paper
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008cited by this paper
• Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production.

  2008cited by this paper
• The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

  2008cited by this paper
• The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorption.

  2008cited by this paper
• The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

  2008cited by this paper
• Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans

  2008cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group

  2008cited by this paper
• Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.

  2008cited by this paper
• Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability.

  2008cited by this paper
• Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.

  2008cited by this paper
• Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

  2008cited by this paper
• Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content

  2008cited by this paper
• Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.

  2008cited by this paper
• Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone.

  2008cited by this paper
• Both Intestinal and Hepatic Lipoprotein Production Are Stimulated by an Acute Elevation of Plasma Free Fatty Acids in Humans

  2008cited by this paper
• Why is HDL functionally deficient in type 2 diabetes?

  2008cited by this paper
• The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes.

  2007cited by this paper
• Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies

  2007cited by this paper
• Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

  2007cited by this paper
• Rosiglitazone and cardiovascular risk.

  2007cited by this paper
• Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse.

  2007cited by this paper
• Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats.

  2007cited by this paper
• Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system.

  2007cited by this paper
• Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

  2007cited by this paper
• Tumor Necrosis Factor-α Induces Intestinal Insulin Resistance and Stimulates the Overproduction of Intestinal Apolipoprotein B48-Containing Lipoproteins

  2007cited by this paper
• Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.

  2007cited by this paper
• Rosiglitazone and cardiotoxicity--weighing the evidence.

  2007cited by this paper
• PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein.

  2007cited by this paper
• PPARγ regulates adipose triglyceride lipase in adipocytes in vitro and in vivo

  2007cited by this paper
• Rosiglitazone and cardiovascular risk.

  2007cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1α and PPARβ/δ gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus

  2007cited by this paper
• The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Peroxisome proliferator‐activated receptor γ agonists inhibit adipocyte expression of α1‐acid glycoprotein

  2007cited by this paper
• Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann–Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

  2006cited by this paper
• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

  2006cited by this paper
• Zonulin Upregulation Is Associated With Increased Gut Permeability in Subjects With Type 1 Diabetes and Their Relatives

  2006cited by this paper
• Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin

  2006cited by this paper
• Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition.

  2006cited by this paper
• The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice1 Published, JLR Papers in Press, June 1, 2006.

  2006cited by this paper
• Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.

  2005cited by this paper
• Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Low density lipoprotein non-esterified fatty acids and lipoprotein lipase in diabetes.

  2005cited by this paper
• GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo.

  2005cited by this paper
• Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster.

  2005cited by this paper
• AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells*

  2004cited by this paper
• Cholesterol metabolism in type 1 diabetes.

  2004cited by this paper
• Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients.

  2004cited by this paper
• PPARs and the complex journey to obesity

  2004cited by this paper
• Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

  2003cited by this paper
• Diabetes: mellitus or lipidus?

  2003cited by this paper
• Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly?

  2002cited by this paper
• Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes.

  2002cited by this paper
• Defective Chylomicron Synthesis as a Cause of Delayed Particle Clearance in Diabetes?

  2002cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.

  2000cited by this paper
• The Relationship Between Cholesterol Absorption and Intestinal Cholesterol Synthesis in the Diabetic Rat Model

  2000cited by this paper
• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  2000cited by this paper
• Cholesterol Absorption, Synthesis, and LDL Metabolism in NIDDM

  1997cited by this paper
• Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?

  1993cited by this paper
• Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: Relationship with control

  1981cited by this paper
• Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption

  year unknowncited by this paper

• The Role of Abnormal Ketone Bodies During Insulin Deficiency in Streptozotocin Induced Diabetes

  2016cites this paper
• GENDER DIFFERENCES OF LIPID PROFILE IN TYPE 2 DIABETES MELLITUS

  2012cites this paper
• RLIP76, a Glutathione-Conjugate Transporter, Plays a Major Role in the Pathogenesis of Metabolic Syndrome

  2011cites this paper
• Consumption of Soymilk Lowers Atherogenic Lipid Fraction in Healthy Individuals

  2011cites this paper
• Influence of rutin treatment on biochemical alterations in experimental diabetes.

  2010cites this paper